{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:55Z","timestamp":1791912475355,"version":"4.3.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T00:00:00Z","timestamp":1751673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Zilucoplan, a peptide complement component 5 (C5) inhibitor, is self-administered as a subcutaneous (SC) injection, which offers an alternative to intravenous infusion of antibody-based complement C5 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate subcutaneous zilucoplan in adults with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG) who switched from intravenous complement C5 inhibitors to zilucoplan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>MG0017 (NCT05514873) was a phase IIIb, open-label, single-arm study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Eligible patients had clinically stable gMG on an intravenous complement C5 inhibitor and were willing to switch to zilucoplan. Patients received a 12-week treatment period of daily subcutaneous zilucoplan 0.3\u2009mg\/kg. Incidence of treatment-emergent adverse events (TEAEs) was the primary endpoint. Change from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score at Week 12 was a secondary endpoint. Treatment preference (Week 12) and treatment satisfaction (9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9)) were both exploratory endpoints. Assessments by prior intravenous complement C5 inhibitor were conducted post hoc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty-six patients enrolled and received zilucoplan; 16 switched from eculizumab and 10 from ravulizumab. TEAEs occurred in 19\/26 (73.1%) patients and were mostly mild in severity. At Week 12, least squares (LS) mean (95% confidence interval) MG-ADL scores improved from baseline by \u22121.15 (\u22122.11, \u22120.19),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0217 and Quantitative MG (QMG) scores by \u22121.24 (\u22122.64, 0.16),\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0802. Clinically meaningful improvement from baseline in mean MG-ADL and QMG scores was observed at Week 12 among patients who switched from ravulizumab (\u22122.41 (\u22124.52, \u22120.30;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0307) and \u22123.52 (\u22126.14, \u22120.90;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.0149), respectively). At Week 12, 76.9% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200920) patients preferred subcutaneous injection compared with intravenous infusion. Mean (standard deviation) changes from baseline in the TSQM-9 Global Satisfaction, Effectiveness and Convenience subscores at Week 12 were +19.410 (27.429), +13.889 (21.534) and +21.739 (19.955), respectively. Complement inhibition increased from baseline and was complete (&gt;95%) by Week 2 and maintained to Week 12.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Zilucoplan demonstrated a favourable safety profile. gMG symptoms improved during zilucoplan treatment; this was clinically meaningful for those switching from ravulizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov (NCT05514873); 22 August 2022.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05514873\">https:\/\/clinicaltrials.gov\/study\/NCT05514873<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251347283","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T08:11:17Z","timestamp":1751703077000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study"],"prefix":"10.1177","volume":"18","author":[{"given":"Miriam","family":"Freimer","sequence":"first","affiliation":[{"name":"Department of Neurology, The Ohio State University Wexner Medical Center, 395 West 12th Avenue, 7th Floor, Columbus, OH 43210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvi","family":"Desai","sequence":"additional","affiliation":[{"name":"Atrium Health, Wake Forest University, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Govindarajan","sequence":"additional","affiliation":[{"name":"HSHS St. Elizabeth\u2019s Hospital, O\u2019Fallon, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min K.","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaida","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupendra","family":"Khatri","sequence":"additional","affiliation":[{"name":"The Regional MS Center and Center for Neurological Disorders, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Levine","sequence":"additional","affiliation":[{"name":"HonorHealth Neurology, Bob Bov\u00e9 Neuroscience Institute, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Macwan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Eisenhower Health, Rancho Mirage, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Neurology and Pediatrics, University of California Los Angeles, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Washington Medical Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Bloemers","sequence":"additional","affiliation":[{"name":"UCB, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Boroojerdi","sequence":"additional","affiliation":[{"name":"UCB, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eumorphia Maria","family":"Delicha","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Lavrov","sequence":"additional","affiliation":[{"name":"UCB, Monheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Neurology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,7,5]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1897567"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00080-7"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066"},{"key":"e_1_3_4_8_2","unstructured":"Alexion Pharmaceuticals Inc. SOLIRIS (eculizumab) injection US PI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125166s447lbl.pdf (2024 accessed June 2025)."},{"key":"e_1_3_4_9_2","unstructured":"Alexion Pharmaceuticals Inc. ULTOMIRIS (ravulizumab-cwvz) injection US PI https:\/\/alexion.com\/documents\/ultomiris_uspi (2024 accessed June 2025)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213920"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241243186"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0171"},{"key":"e_1_3_4_15_2","unstructured":"Alexion Europe SAS. ULTOMIRIS (ravulizumab-cwvx) injection EU SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf (2025 accessed June 2025)."},{"key":"e_1_3_4_16_2","unstructured":"Alexion Europe SAS. SOLIRIS (eculizumab) injection EU SmPC https:\/\/www.medicines.org.uk\/emc\/product\/362\/smpc (2025 accessed June 2025)."},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22140"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23988"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-023-00594-8"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2012.04.007"},{"key":"e_1_3_4_25_2","unstructured":"UCB Pharma S.A. ZILBRYSQ (zilucoplan) injection EU SmPC https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zilbrysq-epar-product-information_en.pdf (2024 accessed June 2025)."},{"key":"e_1_3_4_26_2","volume-title":"Concomitant intravenous immunoglobulin or plasma exchange has no effect on complement inhibition by zilucoplan","author":"Weiss MD","year":"2024","unstructured":"Weiss MD, Hewamadduma C, Leite IM, et al. Concomitant intravenous immunoglobulin or plasma exchange has no effect on complement inhibition by zilucoplan [abstract]. Paper presented at the AANEM, Savannah, GA, 2024."},{"key":"e_1_3_4_27_2","unstructured":"UCB Inc. ZILBRYSQ (zilucoplan) injection US PI https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216834s001lbl.pdf (2024 accessed June 2025)."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000205274"},{"key":"e_1_3_4_29_2","volume-title":"Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: a post hoc analysis of the RAISE-XT study","author":"Ruzhansky K","year":"2024","unstructured":"Ruzhansky K, Freimer M, Leite IM, et al. Compliance to daily self-administered subcutaneous zilucoplan in patients with generalized myasthenia gravis: a post hoc analysis of the RAISE-XT study [abstract]. Paper presented at the AANEM, Savannah, GA, 2024."}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251347283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251347283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251347283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:05:40Z","timestamp":1767675940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251347283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,5]]},"references-count":28,"alternative-id":["10.1177\/17562864251347283"],"URL":"https:\/\/doi.org\/10.1177\/17562864251347283","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,5]]},"article-number":"17562864251347283"}}